We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04294160
Recruitment Status : Active, not recruiting
First Posted : March 3, 2020
Last Update Posted : May 15, 2023
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A phase Ib, open-label platform study of select drug combinations chosen in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies.

Condition or disease Intervention/treatment Phase
BRAF V600 Colorectal Cancer Drug: Dabrafenib Drug: LTT462 Drug: Trametinib Drug: LXH254 Drug: TNO155 Biological: Spartalizumab Biological: Tislelizumab Phase 1

Detailed Description:
This is a phase Ib, multi-center, open-label study with multiple treatment arms in adult patients with advanced or metastatic BRAF V600 (E, D, or K) in order to characterize safety and tolerability of each treatment arm tested and to identify recommended doses and regimens for future studies. The open platform design of this study is adaptive to allow removal of combination treatment arm(s) based on emerging data and facilitate introduction of new candidate combinations. The study is comprised of a dose escalation part and may be followed by a dose expansion part for any combination treatment arm.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 122 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer
Actual Study Start Date : July 22, 2020
Estimated Primary Completion Date : February 23, 2024
Estimated Study Completion Date : February 23, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Medicines

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Dabrafenib + LTT462 backbone arm 1
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: LTT462
Capsule for oral use
Experimental: Dabrafenib + LTT462 + trametinib triplet arm 1
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: LTT462
Capsule for oral use

Drug: Trametinib
Tablet for oral use
Other Name: TMT212, Mekinist
Experimental: Dabrafenib + LTT462 + LXH254 triplet arm 2
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: LTT462
Capsule for oral use

Drug: LXH254
Tablet for oral use
Experimental: Dabrafenib + LTT462 + TNO155 triplet arm 3
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: LTT462
Capsule for oral use

Drug: TNO155
Capsule for oral use
Experimental: Dabrafenib + LTT462 + spartalizumab triplet arm 4
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer - Arm is closed for further enrollment.
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: LTT462
Capsule for oral use

Biological: Spartalizumab
Liquid in vial (Concentrate for solution for infusion) for intravenous use
Other Name: PDR001
Experimental: Dabrafenib + trametinib + TNO155 triplet arm 5
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: Trametinib
Tablet for oral use
Other Name: TMT212, Mekinist

Drug: TNO155
Capsule for oral use
Experimental: Dabrafenib + LTT462 + Tislelizumab triplet arm 6
dose escalation to determine maximum tolerated dose (MTD)/ Recommended dose (RD) in adult patients with advanced or metastatic BRAF V600 colorectal cancer
 Drug: Dabrafenib
Capsule for oral use
Other Name: DRB436, Tafinlar

Drug: LTT462
Capsule for oral use

Biological: Tislelizumab
Liquid in vial (Concentrate for solution for infusion) for intravenous use
Other Name: VDT482, BGBA317


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence and nature of dose limiting toxicities (DLTs) in the first cycle [ Time Frame: 30 months ]
    To characterize safety and tolerability of each treatment arm tested and identify recommended doses (RD) and regimens for future studies

  2. Incidence and severity of AEs and SAEs, including changes in laboratory values, vital signs, and ECGs [ Time Frame: 34 months ]
    To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies

  3. Frequency of dose interruptions [ Time Frame: 30 months ]
    To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies

  4. Frequency of dose reductions [ Time Frame: 30 months ]
    To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies

  5. Dose intensity [ Time Frame: 30 months ]
    To characterize safety and tolerability of each treatment arm tested and identify recommended doses and regimens for future studies


Secondary Outcome Measures :
  1. AUClast derived from Serum/plasma concentration of individual investigational drugs within combination treatments [ Time Frame: 30 months ]
    To characterize the PK of each investigational drug within each treatment arm

  2. Best overall response (BOR) [ Time Frame: 34 months ]
    To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.

  3. Progression free survival (PFS) [ Time Frame: 34 months ]
    To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.

  4. Overall response rate (ORR) [ Time Frame: 34 months ]
    To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.

  5. Duration of response (DOR) [ Time Frame: 34 months ]
    To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.

  6. Disease control rate (DCR) [ Time Frame: 34 months ]
    To evaluate preliminary anti-tumor activity of each treatment arm per RECIST v1.1.

  7. Change from baseline of the PD marker DUSP6 in tumor tissue (dose escalation only) [ Time Frame: 30 months ]
    To evaluate PD effect in their respective combinations in tumor

  8. AUCtau derived from Serum/plasma concentration of individual investigational drugs within combination treatments [ Time Frame: 30 months ]
    To characterize the PK of each investigational drug within each treatment arm

  9. Cmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments [ Time Frame: 30 months ]
    To characterize the PK of each investigational drug within each treatment arm

  10. Tmax derived from Serum/plasma concentration of individual investigational drugs within combination treatments [ Time Frame: 30 months ]
    To characterize the PK of each investigational drug within each treatment arm


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Patients must be willing to undergo a new tumor biopsy at baseline and during on study therapy. Exceptions may be considered after documented discussion with Novartis.
  • All patients must have a BRAF V600 mutation confirmed by local assessment.
  • Patients with unresectable advanced/metastatic BRAF V600 cancer of the colon or rectum with measurable disease as determined by RECIST v1.1
  • Patients must have documented disease progression following, or are intolerant to, 1 or 2 lines of chemotherapy for advanced/metastatic disease

Key Exclusion Criteria:

  • Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in-situ cervical cancer, or other tumors that will not affect life expectancy
  • Impairment of gastrointestinal function or gastrointestinal disease that may signficantly alter the absorption of study drugs
  • History of or current evidence/risk of retinal verin occlusion or serous retinopathy
  • History of or current interstitial lung disease or non-infectious pneumonitis
  • Patients with a known history of testing positive for HIV
  • Clinically significant cardiac disease at screening
  • Any medical condition that would, in the investigator's judgment, prevent the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.
  • Pregnant or lactating women

Other protocol-defined inclusion/exclusion may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04294160


Locations
Layout table for location information
United States, California
UCLA Medical Center Santa Monica Location
Los Angeles, California, United States, 90095
United States, Massachusetts
Massachusetts General Hospital Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, Tennessee
Sarah Cannon Research Institute SC
Nashville, Tennessee, United States, 37203
United States, Texas
Uni of TX MD Anderson Cancer Cntr
Houston, Texas, United States, 77030
Australia, New South Wales
Novartis Investigative Site
Westmead, New South Wales, Australia, 2145
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1000
Novartis Investigative Site
Leuven, Belgium, 3000
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 1Z5
Germany
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Essen, Germany, 45147
Novartis Investigative Site
Ulm, Germany, 89081
Israel
Novartis Investigative Site
Tel Aviv, Israel, 6423906
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1066 CX
Singapore
Novartis Investigative Site
Singapore, Singapore, 119228
Spain
Novartis Investigative Site
Barcelona, Catalunya, Spain, 08035
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46010
Novartis Investigative Site
Madrid, Spain, 28009
United Kingdom
Novartis Investigative Site
Manchester, United Kingdom, M20 4BX
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT04294160    
Other Study ID Numbers: CADPT01C12101
First Posted: March 3, 2020    Key Record Dates
Last Update Posted: May 15, 2023
Last Verified: May 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
Phase Ib, BRAF-mutated, BRAF V600E, BRAF V600D, BRAF V600K, colorectal cancer, colon cancer, rectal cancer, metastatic, BLRM with EWOC
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
 Tislelizumab
Spartalizumab
Trametinib
Dabrafenib
Naporafenib
Antineoplastic Agents, Immunological
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immune Checkpoint Inhibitors